title: Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism.
abstract: The aim of this observational preliminary trial was to estimate the association between the most common polymorphism of LH (LH-beta variant: v-betaLH), with different profiles of ovarian response to recombinant human FSH (rhFSH). A total of 60 normogonadotrophic patients undergoing a gonadotrophin-releasing hormone analogue long down-regulation protocol followed by stimulation with recombinant human FSH (rhFSH) for IVF/intracytoplasmic sperm injection, and in whom at least five oocytes were retrieved were retrospectively included. On the basis of the total rhFSH consumption, patients were divided into three groups: Group A: 22 women requiring a cumulative dose of rhFSH >3500 IU; Group B: 15 patients requiring 2000-3500 IU; Group C (control): 23 women requiring <2000 IU. The presence of v-betaLH was evaluated using specific immunoassays. Peak oestradiol concentrations were significantly lower in Group A when compared with both groups B (P < 0.05) and C (P < 0.001). Group A had a significantly lower (P < 0.05) number of oocytes retrieved (7.3 +/- 1.5, 11.7 +/- 2.4 and 14.7 +/- 4.1 in the three groups, respectively). Seven carriers (31.8%) of v-betaLH were found in Group A, whereas only one variant (6.7%) was observed in Group B; no variant was detected in Group C. These preliminary results suggest that v-betaLH is more frequent in women with ovarian resistance to rhFSH.
authors.affiliation: Dipartimento Universitario di Scienze Ostetriche Ginecologiche e Medicina della Riproduzione, Area Funzionale di Medicina della Riproduzione ed Endoscopia Ginecologica, Università degli Studi di Napoli Federico II, Naples, Italy. alviggi@unina.it
authors.forename: C
authors.initials: C
authors.lastname: Alviggi
authors.forename: R
authors.initials: R
authors.lastname: Clarizia
authors.forename: K
authors.initials: K
authors.lastname: Pettersson
authors.forename: A
authors.initials: A
authors.lastname: Mollo
authors.forename: P
authors.initials: P
authors.lastname: Humaidan
authors.forename: I
authors.initials: I
authors.lastname: Strina
authors.forename: M
authors.initials: M
authors.lastname: Coppola
authors.forename: A
authors.initials: A
authors.lastname: Ranieri
authors.forename: M
authors.initials: M
authors.lastname: D'Uva
authors.forename: G
authors.initials: G
authors.lastname: De Placido
mesh_terms: D000328:Adult; D019943:Amino Acid Substitution / Q000502:physiology; D002986:Clinical Trials as Topic; D004351:Drug Resistance / Q000235:genetics*; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D005787:Gene Frequency; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000235:genetics*; D010060:Ovulation / Q000097:blood / Q000235:genetics; D010062:Ovulation Induction / Q000379:methods*; D020641:Polymorphism, Single Nucleotide / Q000502:physiology*; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; C083781:LHRH, Ala(6)-Gly(10)-ethylamide-; D007986:Luteinizing Hormone